Search results
Results from the WOW.Com Content Network
The journal covers genetic testing research along with associated ethical, legal, social, and economic issues. Related genetic testing coverage includes risk assessment, genetic counseling, carrier detection, novel instrumentation, and cytogenetics. [1] It is the official journal of Genetic Alliance. [1] [2]
[3] [4] [5] Breast cancer is consensually considered genetically and clinically as a heterogeneous disease, in that it reflects the heterogeneity of the normal breast tissue at its origin17873350. [6] A number of discrete genetic events have to occur in order to enable individual tumor cells that have the capacity to grow at an ectopic site.
BioTechniques: the International Journal of Life Science Methods is a peer-reviewed open-access scientific journal published by Future Science Group.It covers laboratory methods and techniques that are of broad interest to professional life scientists, as well as scientists from other disciplines (e.g. physics, chemistry, engineering, computer sciences) interested in life science applications ...
Breast Cancer Research is a bimonthly peer-reviewed medical journal covering research into breast cancer. The journal was established in 1999 and is published by BioMed Central . The editor-in-chief is Lewis Chodosh ( University of Pennsylvania ).
Cancer Epidemiology, Biomarkers & Prevention is a peer-reviewed medical journal devoted to research in the field of cancer epidemiology.Topics include descriptive, analytical, biochemical, and molecular epidemiology, the use of biomarkers to study the neoplastic and preneoplastic processes in humans, chemoprevention and other types of prevention trials, and the role of behavioral factors in ...
MammaPrint is a prognostic and predictive diagnostic test for early stage breast cancer patients that assess the risk that a tumor will metastasize to other parts of the body. [1] It gives a binary result, high-risk or low-risk classification , and helps physicians determine whether or not a patient will benefit from chemotherapy .
Clinical Breast Cancer is a bimonthly peer-reviewed medical journal established in 2000 and published by ... the journal has a 2017 impact factor of 2.703. [1] References
The Oncotype DX® breast cancer assay is one such test used to predict the likelihood of breast cancer recurrence. This test is intended for women with early-stage (Stage I or II), node-negative, estrogen receptor -positive (ER+) invasive breast cancer who will be treated with hormone therapy .